Agenus Inc. (NASDAQ:AGEN - Get Free Report) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $4.15 and traded as high as $8.07. Agenus shares last traded at $7.67, with a volume of 772,906 shares traded.
Wall Street Analyst Weigh In
AGEN has been the subject of a number of recent analyst reports. B. Riley Financial reiterated a "buy" rating and issued a $14.00 price target (up from $8.00) on shares of Agenus in a research note on Thursday, July 30th. Weiss Ratings lowered shares of Agenus from a "sell (d+)" rating to a "sell (d)" rating in a research note on Friday. HC Wainwright reaffirmed a "buy" rating and issued a $25.00 target price (down from $30.00) on shares of Agenus in a report on Tuesday, August 11th. Zacks Research downgraded shares of Agenus from a "strong-buy" rating to a "hold" rating in a research note on Monday, May 11th. Finally, Wall Street Zen cut Agenus from a "strong-buy" rating to a "hold" rating in a report on Monday, August 17th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Agenus has a consensus rating of "Hold" and an average target price of $19.50.
View Our Latest Analysis on Agenus
Agenus Trading Down 5.2%
The business has a 50 day moving average of $5.38 and a two-hundred day moving average of $4.15. The firm has a market cap of $345.30 million, a P/E ratio of 2.97 and a beta of 1.40.
Agenus (NASDAQ:AGEN - Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.06). Agenus had a net margin of 69.33% and a negative return on equity of 47.68%. The business had revenue of $34.52 million for the quarter, compared to analyst estimates of $34.00 million. On average, sell-side analysts predict that Agenus Inc. will post -0.28 EPS for the current year.
Institutional Trading of Agenus
Hedge funds have recently modified their holdings of the stock. EP Wealth Advisors LLC bought a new stake in shares of Agenus during the 4th quarter worth about $31,000. R Squared Ltd acquired a new position in Agenus in the 4th quarter valued at about $41,000. Redwood Family Wealth LLC bought a new position in Agenus in the 4th quarter valued at about $44,000. Quadrature Capital Ltd bought a new position in Agenus in the 4th quarter valued at about $54,000. Finally, Squarepoint Ops LLC acquired a new stake in Agenus during the third quarter worth approximately $54,000. Institutional investors and hedge funds own 61.46% of the company's stock.
About Agenus
(
Get Free Report)
Agenus, Inc NASDAQ: AGEN is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system's response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.
Agenus' pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
